On the morning of Thursday, March 7, the House Ways & Means Committee’s Subcommittee on Health held a hearing titled Promoting Competition to Lower Medicare Drug Prices. The hearing focused a great deal on the effect of patents in the pharmaceutical industry as they relate to pricing. Although some of the Republican membership of the subcommittee pointed out issues with various proposals to limit patent protections for drugmakers, the panel acted largely as a firing squad for patents. In his closing statement, Rep. Doggett expressed his dissatisfaction with the tenor of the day’s debate. “I view it as encouraging that there is bipartisan recognition of the serious problems so many Americans are facing with, really, prescription price gouging,” he said. “The question is whether we’ll have any bipartisan agreement on doing anything about it.”
The post House Health Subcommittee Holds Fractious Hearing on Drug Pricing and Patent Protections appeared first on IPWatchdog.com | Patents & Patent Law.
House Health Subcommittee Holds Fractious Hearing on Drug Pricing and Patent Protections
No Comments
Business
- Patents on Transactions Using Cryptocurrency: Square versus PayPal
- Managing the Perils of Public IP Company Ownership
- IPO Top 300, 2020: Slight Decreases in Patent Grants Due to Budgets, Not COVID
- Pardon Me? Levandowski Case Highlights Need for Proactive Approach to Avoid Trade Secret Problems in Hiring
- How Patents Enable Mavericks and Challenge Incumbents
Recent Posts
- Justices Lean Toward Limiting, Not Eliminating, Assignor Estoppel Doctrine in Minerva v. Hologic
- Kappos at PTAB Masters Day 2: PTAB Problems Arose When It Failed to Evolve
- EPO Opposition Division Upholds NuCana Patent on Gilead’s Sovaldi, Highlighting Potential Flaws of CAFC Ruling in Gilead/Idenix
- Countries Like the Philippines are Unable to Utilize IP Flexibilities to Fight COVID-19
- Why the Patent Classification System Needs an Update